Table 3 Clinicopathological characteristics and prognostic factors of 161 patients with OSCC measured by Apo10-/TKTL1-, Apo10+/TKTL1-, Apo10-/TKTL1+, and Apo10+/TKTL1+ expressors

Age (y)

0.9067

<60 ± 11.8

80 (49.7%)

13 (16%)

32 (40%)

3 (4%)

32 (40%)

≥60 ± 11.8

81 (50.3%)

9 (11%)

39 (48%)

4 (5%)

29 (36%)

Gender

0.3179

Male

122 (75.8%)

18 (15%)

55 (45%)

5 (4%)

44 (36%)

Female

39 (24.2%)

4 (10%)

16 (41%)

2 (5%)

17 (44%)

Site distribution of OSCC

0.4899

Lips

11 (6.8%)

3 (27%)

6 (55%)

0 (0%)

2 (18%)

Tongue

41 (25.5%)

5 (12%)

16 (39%)

3 (7%)

17 (42%)

Floor of the mouth

64 (39.8%)

7 (11%)

30 (47%)

3 (5%)

24 (37%)

Palate

15 (9.3%)

0 (0%)

6 (40%)

0 (0%)

9 (60%)

Buccal mucosa

8 (5.0%)

3 (37.5%)

3 (37.5%)

0 (0%)

2 (25%)

Alveolar ridge

22 (13.7%)

4 (18%)

10 (45%)

1 (5%)

7 (32%)

Histological Grading

0.8621*

G1

41 (25.5%)

8 (19%)

15 (37%)

2 (5%)

16 (39%)

G2

106 (65.8%)

10 (9%)

53 (50%)

5 (5%)

38 (36%)

G3

13 (8.1%)

3 (23%)

3 (23%)

0 (0%)

7 (54%)

G4

1 (0.6%)

1 (100%)

0 (0%)

0 (0%)

0 (0%)

Tumor size

0.0002**

pT1

64 (39.8%)

14 (22%)

32 (50%)

0 (0%)

18 (28%)

pT2

42 (26.1%)

8 (19%)

17 (41%)

3 (7%)

14 (33%)

pT3

17 (10.6%)

0 (0%)

5 (29%)

0 (0%)

12 (71%)

pT4

38 (23.6%)

0 (0%)

17 (45%)

4 (10%)

17 (45%)

Cervical lymph node metastasis

0.0007

pN0

118 (73.3%)

19 (16%)

59 (50%)

4 (3%)

36 (31%)

pN1-3

43 (26.7%)

3 (7%)

12 (28%)

3 (7%)

25 (58%)

UICC stage

<0.0001***

UICC I

48 (29.8%)

12 (25%)

30 (63%)

0 (0%)

6 (12%)

UICC II

36 (22.4%)

8 (22%)

15 (42%)

3 (8%)

10 (28%)

UICC III

31 (19.3%)

1 (3%)

10 (32%)

0 (0%)

20 (65%)

UICC IV

46 (28.6%)

1 (2%)

16 (35%)

4 (9%)

25 (54%)

Locoregional recurrence

<0.0001

No

117 (72.7%)

21 (18%)

60 (51%)

6 (5%)

30 (26%)

Yes

44 (27.3%)

1 (2%)

11 (25%)

1 (2%)

31 (71%)